Promising Advances in Ovarian Cancer Treatment

The Challenge of Advanced Ovarian Cancer

Advanced ovarian cancer presents significant treatment challenges, with over 20,000 Americans diagnosed each year. Tragically, more than half of these patients succumb to the disease, often diagnosed at advanced stages where treatment becomes increasingly difficult. As a result, researchers are actively exploring new therapeutic strategies to enhance treatment efficacy.

Improving Drug Delivery to Tumor Cells

One promising area of research focuses on improving the delivery of chemotherapy drugs to tumor cells. Tumors develop a rigid, mesh-like structure known as the extracellular matrix, which surrounds tumor cells and impedes drug entry. This structural barrier not only increases the overall stiffness of the tumor but also compresses the blood vessels, making it harder for drugs carried in the bloodstream to reach their targets. A potential solution could involve developing drugs that reduce the extracellular matrix, thereby facilitating better access for chemotherapy agents.

The Role of Angiotensin II in Tumor Progression

Recent findings indicate that a protein called angiotensin II contributes to the accumulation of the extracellular matrix and constricts blood vessels, leading to elevated blood pressure. Many individuals with hypertension are already prescribed medications that inhibit angiotensin II. Researchers in the United States have been investigating whether losartan, an angiotensin II blocker, can enhance the effectiveness of chemotherapy for ovarian cancer.

Study Findings on Losartan and Chemotherapy

In a study published in the Proceedings of the National Academy of Sciences, researchers conducted experiments on mice injected with ovarian cancer cells. The mice were treated with losartan, the chemotherapy drug paclitaxel, or a combination of both. Results showed that while losartan alone had no effect, paclitaxel slowed tumor growth. Notably, the combination of paclitaxel and losartan resulted in tumors that weighed half as much as those treated with paclitaxel alone.

Impact of Blood Pressure Medications on Patient Survival

Given that many ovarian cancer patients also experience high blood pressure, researchers evaluated the survival of 123 patients taking angiotensin II-limiting medications compared to 99 patients on other blood pressure drugs. Findings revealed that patients on angiotensin II inhibitors lived nearly twice as long, with an average survival of 63 months post-diagnosis, versus 33 months for those on other blood pressure medications. Notably, patients using angiotensin II receptor blockers like losartan demonstrated even longer survival rates.

Future Directions for Research

While the observational nature of this clinical study limits its conclusions, it highlights the potential of losartan and similar drugs in improving outcomes for ovarian cancer patients. To establish a more definitive link, future clinical trials should randomly assign patients to receive chemotherapy with or without angiotensin II blockers. Despite the current limitations, the findings are encouraging and suggest that incorporating losartan into treatment regimens could significantly extend survival for patients with advanced ovarian cancer. The affordability and relative safety of losartan further enhance its appeal as a potential therapeutic option.

Conclusion

The exploration of losartan as a treatment adjunct in ovarian cancer is a significant step forward. An effective treatment that could nearly double the survival time of patients with advanced disease would represent a major advancement in oncology.

Related Topics of Interest

– Effective Ways to Lower High Blood Pressure
– Targeting Immune Cells to Treat High Blood Pressure
– Do Nitrate-Rich Vegetables Lower High Blood Pressure?
– Effects of Mediterranean Diet on Endothelial Function and Blood Pressure
– Does Dietary Nitrate Help Decrease High Blood Pressure?
– Can a Home Blood Pressure Monitor Predict Disease Risk?

References

Zhao, Y., et al. “Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.” Proceedings of the National Academy of Sciences, 201818357 (2019).
“Antihypertension drug losartan may improve treatment of ovarian cancer.” Massachusetts General Hospital (January 15, 2019). Accessed at: https://www.massgeneral.org/News/pressrelease.aspx?id=2339